知识与财富的链接
目的 探讨盐酸坦洛新缓释片改善慢性前列腺炎/慢性盆腔疼痛综合征(CP/CPPS)临床症状的疗效.方法 自2008年9月～2009年12月,选择CP/CPPS患者80例,随机分为两组,每组40人,A组给予α1-受体阻滞剂盐酸坦洛新缓释片0.2mg,每晚1次,连服4周+双氯芬酸钠缓释片,75mg,每日1次,连服4周;B组给予双氯芬酸钠缓释片,75mg,每日1次,连服4周.按慢性前列腺炎症状评分表(NIH-CPSI)记录治疗前后患者症状评分,并行尿动力学检查,监测患者治疗前后变化.结果 经过4周服药治疗,患者症状明显好转,患者的NIH-CPSI评分以及平均尿流率、最大尿流率、残余尿等尿动力学指标明显变化,差异有统计学意义.结论 盐酸坦洛新缓释片可明显改善CP/CPPS临床症状,提高患者的生活质量,值得临床上广泛应用.
ObjectiveTo investigate the validity of tamsulosin hydrochloride sustained-release tablets in the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). MethodsFrom September 2008 to December 2009, 80 patients with the CP/CPPS were randomly divided into two groups with each group 40 cases.Patients in A group were given α1-receptor blocker tamsulosin hydrochloride sustained-release tablets 0.2mg qn for 4 weeks,and diclofenac sodium sustained-release tablets 75mg qd for 4 weeks.Patients in B group were given diclofenac sodium sustained-release tablets 75mg qd for 4 weeks. The chronic prostatitis symptom score sheet (NIH-CPSI), parallel urodynamics before and after treatment in patients were recorded and compared. ResultsAfter 4 weeks of medication treatment, the patient′s NIH-CPSI score and the average urinary flow rate, maximum flow rate, residual urine improred obriously and the differences statistical significance.ConclusionTamsulosin hydrochloride sustained release tablets can improve the quality of life and relieve the symptom of patients with the CP/CPPS.It is worthy of wide clinical application.
